General-Purpose Ultrasound Neuromodulation System for Chronic, Closed-Loop Preclinical Studies in Freely Behaving Rodents.
Yehhyun JoSang-Mok LeeTaesub JungGijae ParkChanhee LeeGeun Ho ImSeongju LeeJin Soo ParkChaerin OhGeon KookHyunggug KimSeongyeon KimByung Chul LeeGreg S B SuhSeong-Gi KimJeongyeon KimHyunjoo Jenny LeePublished in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2022)
Transcranial focused ultrasound stimulation (tFUS) is an effective noninvasive treatment modality for brain disorders with high clinical potential. However, the therapeutic effects of ultrasound neuromodulation are not widely explored due to limitations in preclinical systems. The current preclinical studies are head-fixed, anesthesia-dependent, and acute, limiting clinical translatability. Here, this work reports a general-purpose ultrasound neuromodulation system for chronic, closed-loop preclinical studies in freely behaving rodents. This work uses microelectromechanical systems (MEMS) technology to design and fabricate a small and lightweight transducer capable of artifact-free stimulation and simultaneous neural recording. Using the general-purpose system, it can be observed that state-dependent ultrasound neuromodulation of the prefrontal cortex increases rapid eye movement (REM) sleep and protects spatial working memory to REM sleep deprivation. The system will allow explorative studies in brain disease therapeutics and neuromodulation using ultrasound stimulation for widespread clinical adoption.
Keyphrases
- working memory
- magnetic resonance imaging
- case control
- cell therapy
- contrast enhanced ultrasound
- ultrasound guided
- prefrontal cortex
- white matter
- physical activity
- liver failure
- emergency department
- stem cells
- transcranial direct current stimulation
- small molecule
- sleep quality
- magnetic resonance
- drug induced
- attention deficit hyperactivity disorder
- electronic health record
- computed tomography
- mesenchymal stem cells
- hepatitis b virus
- resting state
- blood brain barrier
- cerebral ischemia
- adverse drug